• Standigm

  Participated · Equity · Mar 2021

  Standigm develops workflow AI technology that spans novel target identification, lead generation, and drug repurposing through proprietary platforms such as Standigm ASK™, Standigm BEST™, Standigm Insight™ and the automated DarkMolFactory™. The company says it can generate first-in-class lead compounds within seven months and currently runs 22 in-house or collaborative drug pipelines. The recent $10 million investment will be used for clinical research of AI-driven drug compounds to strengthen Standigm’s competitiveness in the global market. Standigm has completed a series of investments from SK Chemicals and Pavilion Capital following a Pre-IPO funding round in March. NH Investment & Securities has been in charge of Standigm’s IPO process since March last year, indicating an ongoing push toward public markets. Founded in 2015 and headquartered in Seoul, Standigm is pursuing full-stack, AI-driven industrialization of drug discovery by automating molecular design and expanding automation across the discovery process. Standigm applies proprietary AI platforms to industrialize drug discovery, covering target identification, lead generation, repurposing, and automated molecular design. Its platforms include Standigm ASK™ for target discovery, Standigm BEST™ for lead selection, Standigm Insight™ for repurposing, and DarkMolFactory™ for automated molecular design. The company reports more than 20 preclinical pipelines and collaborations with over ten pharmaceutical or academic partners, including SK chemicals, Hanmi Pharmaceuticals, HK inno.N, and Samjin Pharmaceutical. Standigm and SK holdings C&C opened the iCLUE&ASK™ target-identification platform to the public in September. Management says proceeds from the recent financing will bolster B2B sales and support FDA investigational new drug (IND) filings and global collaborations. Standigm holds two patents for its AI technology granted in 2021 and has repurposed an FDA-approved drug for rheumatoid arthritis with a partner and filed for a patent.

• ILIAS Biologics

  Participated · Series B · Oct 2020

  Ilias Biologics develops exosome-based therapeutics using its EXPLOR® platform, a novel protein-loading method that enables free-form loading of large therapeutic proteins into exosome lumens. The company’s lead candidate, ILB-202, produced promising preclinical data published in Science Advances, and Ilias secured a key exosome engineering patent from the USPTO in July. The Series B proceeds will support continued development of the EXPLOR platform and advancement of its exosome therapeutics pipeline across inflammatory diseases and oncology. Ilias plans to submit an IND to the U.S. FDA and initiate a first-in-human clinical trial by the second half of 2021 targeting an undisclosed acute inflammatory disease, and is in active discussions with multiple pharmaceutical companies for potential collaborations. Financially, the company has raised a total of $40.2M since its foundation in November 2015. Management is led by CEO Dr. Chulhee Choi and is planning an IPO on KOSDAQ in Q1 2022, with underwriter contracts being finalized.

No current team members are available.